Stereotaxis (NYSEAMERICAN:STXS) Announces Earnings Results

Stereotaxis (NYSEAMERICAN:STXS) released its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $8.35 million. Stereotaxis had a negative net margin of 69.50% and a negative return on equity of 163.30%.

Here are the key takeaways from Stereotaxis’ conference call:

• Recurring revenue reached $6.2 million in Q2, driven by the launch of MAGiC and a 270% sequential increase in robotic catheter revenue. Management expects recurring revenue to rise to approximately $7 million in Q3 and $8 million in Q4.
• MAGiC adoption is expanding, with roughly a dozen U.S. hospitals approved to purchase the catheter and procedure-level disposable revenue generally in the $5,000–$8,000-plus range. Demand currently exceeds supply, but the company expects about $1 million of incremental catheter revenue in each of the next two quarters as manufacturing ramps.
• Stereotaxis received its first U.S. GenesisX order and expects installation this fall alongside a non-modified X-ray, supporting formal compatibility with that manufacturer. Synchrony also generated initial orders and is expected to contribute more than $1 million of system revenue per quarter in the near term.
• Q2 revenue was $7.7 million, down year over year because no robotic system was delivered, while the company posted a $4.5 million net loss and $3.7 million of negative free cash flow. Gross margins remained pressured by low manufacturing volumes, and management acknowledged ongoing adoption barriers including catheter supply, GenesisX validation, and X-ray compatibility.
• Management reiterated its expectation of reaching cash-flow profitability in the first half of 2027 without additional financing, assuming continued catheter adoption and modest system sales. The company also highlighted longer-term growth opportunities from a wireless/mobile robot, pulse-field-ablation catheters, AI-enabled surgery, and the recently completed Robocath acquisition.

Stereotaxis Price Performance

Shares of Stereotaxis stock traded down $0.06 during trading on Wednesday, hitting $1.40. 1,372,072 shares of the company’s stock traded hands, compared to its average volume of 608,693. Stereotaxis has a 1 year low of $1.24 and a 1 year high of $3.59. The business has a 50-day simple moving average of $1.63 and a 200-day simple moving average of $1.87. The stock has a market capitalization of $137.10 million, a P/E ratio of -5.83 and a beta of 1.37.

Analyst Upgrades and Downgrades

STXS has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $3.50 target price (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Citigroup reissued a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday, June 3rd. Finally, TD Cowen decreased their price objective on shares of Stereotaxis from $5.00 to $3.00 and set a “buy” rating for the company in a report on Wednesday. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Stereotaxis has an average rating of “Buy” and an average target price of $3.70.

Hedge Funds Weigh In On Stereotaxis

Several hedge funds and other institutional investors have recently bought and sold shares of STXS. AlphaCentric Advisors LLC bought a new position in Stereotaxis in the fourth quarter valued at about $1,380,000. Two Sigma Investments LP purchased a new position in Stereotaxis in the third quarter worth about $1,125,000. Vanguard Group Inc. grew its stake in shares of Stereotaxis by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after purchasing an additional 138,482 shares during the period. Envestnet Asset Management Inc. bought a new stake in shares of Stereotaxis during the 3rd quarter valued at about $413,000. Finally, Rhumbline Advisers increased its position in shares of Stereotaxis by 223.7% during the 2nd quarter. Rhumbline Advisers now owns 148,913 shares of the company’s stock valued at $316,000 after purchasing an additional 102,916 shares during the last quarter. Institutional investors own 45.35% of the company’s stock.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.